英富商布蘭森旗下維珍銀河(SPCE.US)配股集資最多5億美元 股價挫近19%
英國富商布蘭森旗下太空旅行初創維珍銀河(Virgin Galactic)(SPCE.US)宣佈計劃發債集資最多5億美元,股價跌18.9%報10.03美元。
公司計劃私人配售2027年到期可換股優先票據,集資4.25億美元,並設額外配售7,500萬美元選項。公司計劃把集資所得用作營運資金、一般及財務開支,以及加快開發太空艙。
維珍銀河透過與特殊目的收購公司(SPAC)合併借殼上市,公司原預計在2020年接載客戶上太空旅行。布蘭森及3名公司員工去年7月進行試飛,公司目前預期最快今年可提供太空旅行服務。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.